This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Alkermes' CEO Presents At Morgan Stanley Global Healthcare Conference (Transcript)

And those two elements are rare to find in biopharmaceutical companies, particularly of our current size. So on the financial here and now, we have assembled based on our technologies, which are, I think fairly easily understood, now they are quite advanced.

We have a pipeline or portfolio of five major commercial products and these are commercial products approved in markets around the world. Five products that are almost all of them early in their commercial life with long patent protection, patent protections 20s for the most part.

So these five commercial products are contributing topline now, which is about a $0.5 billion and growing, that’s generating positive non-GAAP income, positive cash flow, positive EBITDA, and that’s continue to be the case for the foreseeable future.

So we can cross the rubicon. We become an economic enterprise of certain scale with long lived assets that are not interrelated in terms of [their core entities], they are very independent, they comprise of portfolio that’s very power and can last for long time.

It originates from a certain technical capability, manufacturing capability that we built over the last couple decades. So the probability we think of our being able to build more products is quite high.

The difference between the next-generation of products and the first generation of products, is that the first generation of products were essentially done under a partnering model, where we used big pharmas money and resources, and development expertise to help us build our capabilities and generate cash flows from royalties and manufacturing products.

This next wave of products, our proprietary products that comprise the pipeline take that learning and that understanding the technology and apply to drug for Elan account. This is not a new story. This is what Elan did a couple decade or so ago and transform themselves into a $10 billion plus company.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs